page contents

Tag Archives: Bioservices

Catalent reportedly to buy Paragon Bioservices for $1.2 billion

Catalent said on Monday it would buy privately held gene therapy-focused Paragon Bioservices in an all-cash deal for $ 1.2 billion, helping the drug developer expand its capabilities to make specialized and costly treatments. Paragon, backed by private-equity firms Camden Partners and NewSpring Capital, focuses on developing and manufacturing products such as complex biopharmaceuti… Health and Science

Read More »

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close